title: Production of antibodies with peptide-CpG-DNA-liposome complex without carriers.
abstract: BACKGROUND
  The screening of peptide-based epitopes has been studied extensively for the purpose of developing therapeutic antibodies and prophylactic vaccines that can be potentially useful for treating cancer and infectious diseases such as influenza virus, malaria, hepatitis B, and HIV. To improve the efficacy of antibody production by epitope-based immunization, researchers evaluated liposomes as a means of delivering vaccines; they also formulated adjuvants such as flagella and CpG-DNA to enhance the magnitude of immune responses. Here, we provide a potent method for peptide-based epitope screening and antibody production without conventional carriers.
  
  
  RESULTS
  We present that a particular form of natural phosphodiester bond CpG-DNA encapsulated in a specific liposome complex (Lipoplex(O)) induces potent immunomodulatory activity in humans as well as in mice. Additionally, Lipoplex(O) enhances the production of IgG2a specific to antigenic protein in mice. Most importantly, immunization of mice with several peptides co-encapsulated with Lipoplex(O) without carriers significantly induces each peptide-specific IgG2a production in a TLR9-dependent manner. A peptide-specific monoclonal antibody produced against hepatocellular carcinoma-associated antigen has functional effects on the cancer cells.
  
  
  CONCLUSIONS
  Our overall results show that Lipoplex(O) is a potent adjuvant and that complexes of peptide and Lipoplex(O) are extremely useful for B cell epitope screening and antibody production without carriers. Therefore, our strategy may be promptly used for the development of therapeutic antibodies by rapid screening of potent B cell epitopes.
authors: Department of Microbiology, College of Medicine, Hallym University, Gangwon-do 200-702, Republic of Korea.
authors: Dongbum
authors: D
authors: Kim
authors: Sanghoon
authors: S
authors: Kwon
authors: Jae Won
authors: JW
authors: Rhee
authors: Kwang Dong
authors: KD
authors: Kim
authors: Young-Eun
authors: YE
authors: Kim
authors: Cheung-Seog
authors: CS
authors: Park
authors: Myeong Jun
authors: MJ
authors: Choi
authors: Jun-Gyo
authors: JG
authors: Suh
authors: Doo-Sik
authors: DS
authors: Kim
authors: Younghee
authors: Y
authors: Lee
authors: Hyung-Joo
authors: HJ
authors: Kwon
references: J Virol. 1996 May;70(5):2852-60
references: 8627759
references: Biochem Biophys Res Commun. 2009 Feb 6;379(2):362-7
references: 19103173
references: Nat Rev Drug Discov. 2006 Jun;5(6):471-84
references: 16763660
references: J Clin Invest. 1996 Sep 1;98(5):1119-29
references: 8787674
references: Curr Opin Biotechnol. 2004 Dec;15(6):518-29
references: 15560978
references: Int Immunol. 1999 Jul;11(7):1043-51
references: 10383936
references: Expert Rev Vaccines. 2007 Dec;6(6):939-48
references: 18034655
references: J Virol. 1994 Aug;68(8):5321-5
references: 8035532
references: Nat Med. 1999 Jun;5(6):702-5
references: 10371511
references: J Immunol. 1996 Sep 1;157(5):1840-5
references: 8757300
references: Adv Enzymol Relat Areas Mol Biol. 1978;47:45-148
references: 364941
references: J Natl Cancer Inst. 1984 Apr;72(4):955-62
references: 6200641
references: Cancer Res. 2004 Dec 1;64(23):8754-60
references: 15574787
references: J Drug Target. 1996;3(6):469-75
references: 8863139
references: Vaccine. 2003 Jul 4;21(23):3319-29
references: 12804863
references: Expert Rev Vaccines. 2007 Aug;6(4):591-603
references: 17669012
references: J Immunol. 2005 May 15;174(10):6129-36
references: 15879108
references: Annu Rev Immunol. 2002;20:709-60
references: 11861616
references: J Immunol. 2007 Jul 1;179(1):31-5
references: 17579017
references: Nature. 2000 Dec 7;408(6813):740-5
references: 11130078
references: EMBO J. 1998 Nov 2;17(21):6230-40
references: 9799232
references: J Immunol. 1998 Jan 15;160(2):870-6
references: 9551923
references: Curr Protoc Immunol. 2006 Sep;Chapter 2:Unit 2.5
references: 18432969
references: J Immunol. 2001 Sep 15;167(6):3324-8
references: 11544321
references: Trends Mol Med. 2002 Mar;8(3):114-21
references: 11879771
references: J Clin Invest. 2008 Apr;118(4):1354-66
references: 18357344
references: Curr Opin Biotechnol. 1997 Aug;8(4):442-8
references: 9265723
references: Mol Immunol. 2004 Aug;41(10):955-64
references: 15302158
references: Blood. 1994 Dec 1;84(11):3660-6
references: 7949121
references: Cancer Res. 1988 Feb 1;48(3):589-601
references: 3335022
references: J Virol. 1985 Sep;55(3):836-9
references: 2991600
references: J Immunol. 1999 Feb 15;162(4):2368-74
references: 9973517
references: J Immunol. 1991 Sep 15;147(6):1759-64
references: 1890302
references: Biosci Rep. 2002 Apr;22(2):339-53
references: 12428909
references: Nat Med. 2006 Aug;12(8):905-7
references: 16862151
references: J Exp Med. 1997 Nov 17;186(10):1621-2
references: 9411016
references: Nucleic Acids Res. 1988 Apr 25;16(8):3209-21
references: 2836790
references: Mol Immunol. 2006 May;43(13):2107-18
references: 16442622
references: J Exp Med. 1997 Nov 17;186(10):1623-31
references: 9362523
references: Biochemistry. 1986 Sep 23;25(19):5425-32
references: 2430611
references: FEBS Lett. 1990 Dec 10;276(1-2):172-4
references: 1702393
references: Adv Drug Deliv Rev. 2004 Apr 23;56(7):947-65
references: 15066754
references: J Immunol. 2005 Sep 15;175(6):3569-76
references: 16148100
references: Nature. 1995 Apr 6;374(6522):546-9
references: 7700380
references: Nat Med. 2004 Feb;10(2):187-92
references: 14745443